On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer

We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Moser, Tina, Waldispuehl-Geigl, Julie, Belic, Jelena, Weber, Sabrina, Zhou, Qing, Hasenleithner, Samantha O., Graf, Ricarda, Terzic, Jasmin Alia, Posch, Florian, Sill, Heinz, Lax, Sigurd, Kashofer, Karl, Hoefler, Gerald, Schoellnast, Helmut, Heitzer, Ellen, Geigl, Jochen B., Bauernhofer, Thomas, Speicher, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666126/
https://www.ncbi.nlm.nih.gov/pubmed/33299124
http://dx.doi.org/10.1038/s41698-020-00134-3
Descripción
Sumario:We addressed a significant unknown feature of circulating tumor DNA (ctDNA), i.e., how ctDNA levels change during chemotherapy, by serially monitoring ctDNA in patients with colorectal cancer during the 48-h application of FOLFOX. Surprisingly, we did not observe a spike in ctDNA as a sign of a responsive tumor, but instead ctDNA levels initially decreased and remained low in patients with stable disease or partial response. Our observations reveal further insights into cell destruction during chemotherapy with important implications for the management of patients.

Ejemplares similares